Cha-Seong Lim

Atrogi AB engages in research and development & sells type 2 diabetes (T2D) with minimal side effects. The company was founded by Tore Bengtsson and Andreas Bhagwani in 2013 and is headquartered in Solna, Sweden.

PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.

Prokarium Ltd. operates as a biopharmaceutical company that focuses on developing vaccination solutions based on synthetic biology. Its oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases. The company is headquartered in Keele, the United Kingdom.

Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. Celleron has deep relationships with Oxford University and is located on the Oxford Science Park. The British company focuses on the clinical development of new and innovative therapies to treat cancer. Celleron is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. The company's lead products are currently in clinical trials, and they have a biomarker platform that allows them to identify responsive patients. Celleron Therapeutics Ltd. was founded in 2004, and the CEO is Nick la Thangue.

Pavilion Data Systems, Inc. designs and develops NVMe-oF storage technologies. Its NVMe-over-Fabric Storage Array ingests, processes, stores, and serves an order of magnitude more data for massively-parallel, modern applications. The company was founded by Kiran Malwankar, V. R. Satish, and Sundar Kanthadai in 2014 and is headquartered in San Jose, CA.

Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA.

Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.